Conclusion.-MTX appears to be as effective as CYC for maintenance therapy in patients with severe EGPA; however, these results do not seem to support the hypothesis that it is safer than CYC. Introduction.-The aims of this study were: -to explore the relationship between sputum biomarkers of airway inflammation and levels of asthma severity/control; -to compare eosinophilic markers in induced sputum and blood; -to assess the impact of asthma on the quality of life of the EGPA patients. Methods.-Thirty-two patients (13F:19 M, age 56 AE 13 yrs; follow-up 6 AE 5 yrs) affected by EGPA were enrolled. All patients were assessed for lung function and bronchial hyperreactivity; asthma severity was evaluated according to GINA guidelines and asthma control by ACT test. Sputum eosinophil percentages, exhaled nitric oxide (eNO) and blood EGPA biomarkers were assessed including: eosinophilic count, serum IL-2, IL-4, IL-5, eosinophil cationic protein (ECP) and anti-neutrophil cytoplasmic autoantibody (ANCA). Systemic and inhaled therapy, BVAS and VDI, the short form (SF)-36 and the Asthma Quality of Life Questionnaire (AQLQs) were recorded. Results.-All the patients received low dose oral corticosteroids (CS) and/or immunosuppressive drugs, but only 50% of them were treated with inhaled CS. In all the patients we documented a low disease activity but a severe poorly controlled asthma (table I). Sputum eosinophil counts were correlated with both peripheral eosinophilia (r = 0.487, P = 0.007) and lung function tests (i.e. FEV1, r = À0.404, P = 0.03). A good association was also detected between eNO and ACT (P = 0.04). AQLQs score was significantly correlated with the SF-36 questionnaire score (r = 0.462, P = 0.03). Discussion.-Airway inflammation biomarkers correlated with both asthma severity/clinical control and systemic markers of inflammation. Immunosuppressive drugs are effective in controlling systemic inflammation but not airway inflammation with unfavorable effects on patients' quality of life. Conclusion.-Control of asthma represents a crucial goal of EGPA management. Airway inflammation biomarkers may represent a useful tool in monitoring and tailoring patients' treatment over the follow-up.
Introduction.-The aims of this study were: -to explore the relationship between sputum biomarkers of airway inflammation and levels of asthma severity/control; -to compare eosinophilic markers in induced sputum and blood; -to assess the impact of asthma on the quality of life of the EGPA patients. Methods.-Thirty-two patients (13F:19 M, age 56 AE 13 yrs; follow-up 6 AE 5 yrs) affected by EGPA were enrolled. All patients were assessed for lung function and bronchial hyperreactivity; asthma severity was evaluated according to GINA guidelines and asthma control by ACT test. Sputum eosinophil percentages, exhaled nitric oxide (eNO) and blood EGPA biomarkers were assessed including: eosinophilic count, serum IL-2, IL-4, IL-5, eosinophil cationic protein (ECP) and anti-neutrophil cytoplasmic autoantibody (ANCA). Systemic and inhaled therapy, BVAS and VDI, the short form (SF)-36 and the Asthma Quality of Life Questionnaire (AQLQs) were recorded. Results.-All the patients received low dose oral corticosteroids (CS) and/or immunosuppressive drugs, but only 50% of them were treated with inhaled CS. In all the patients we documented a low disease activity but a severe poorly controlled asthma (table I). Sputum eosinophil counts were correlated with both peripheral eosinophilia (r = 0.487, P = 0.007) and lung function tests (i.e. FEV1, r = À0.404, P = 0.03). A good association was also detected between eNO and ACT (P = 0.04). AQLQs score was significantly correlated with the SF-36 questionnaire score (r = 0.462, P = 0.03). Discussion. 
